Skip to content
you are here


Immuno-Oncology has introduced a modern era in the Oncology Landscape

"Since the entrance of the modern era of immunotherapy, this landscape continues to evolve. The unique mode of action of IO drugs, makes them eminently suitable for combination therapy. At Barc Lab, we are very excited to learn what the future holds and we are ready when you are."

Sofie Vandevyver
Head of Business Operations & Marketing

How Barc Lab can keep you on track and beyond in the ever-evolving Oncology Landscape

Over the last few years, there has been an obvious shift in the field of oncology. The unique mode of action of immuno-Oncology (IO) drugs continues to evolve in the area of personalized medicine. Obviously, CAR-T cell therapies, checkpoint inhibitors and combination therapies have been celebrated as breakthroughs with an increasing amount of FDA approvals. With the almost infinite options in specificity and design, it is very likely that many more immuno-based therapies will enter into clinical research.

This offers opportunities for finding a proper treatment for both solid tumors and onco-hematological malignancies. Clearly, immuno-oncology has hit prime time, but there are still some challenges that remain. One of the key drivers in clinical trials is the toxicity management, efficacy analysis and follow-up. Parameters like tissue distribution, tumor addiction, and surface density must be considered in predicting the safety profile.


Compounding the challenge is finding the proper resources for your clinical trials. With 35 years of experience, Barc Lab is a leader in Oncology clinical trials. Our global solutions comprise a wide range of assays to monitor different aspects during your clinical trial:


  • Immune Therapy into Central Lab Services:
    • Response to Treatment
      • Target presence and immunophenotyping
      • MRD assessment
    • Pharmacokinetics and -dynamics
    • Immunogenicity and ADA
    • Immune Monitoring
      • Behavior
      • Quantification
      • Responsiveness
    • Biomarkers
    • Patient Stratification     
  • Scientific Expertise, including state-of-the-art technologies such as:      
    • Flow Cytometry for immunophenotyping and pharmacokinetics
    • Immunohistochemistry for target presence and stratification
    • Quantitative PCR for CAR-T cell monitoring or Vector Copy Number Analysis (VCN)
    • PCR-based long-term safety testing – Replication Competent Lentivirus (RCL)
    • Immunoassays by ELISA and MSD (cytokines) to measure toxicity (Cytokine Release Syndrome)
    • Electrophoresis for Multiple Myeloma changes
    • Sequencing for MRD and patient stratification
  • Throughput capacity:          
    • Phase I through Phase IV studies   
    • Over 40% oncology trials


Since the entrance of the modern era of immunotherapy, this landscape continues to evolve in a fast-paced manner. If you are excited to learn more about how we keep up and how we can help you, get in touch with us to start the dialogue.

Dominique Slaets, Pharm D

Dominique Slaets, Pharm D, Principal Scientist

Dominique holds a PhD in Pharmaceutical Sciences and joined the Cerba HealthCare group in 2012 as assistant Head of the Hematology Department. She specialized in electrophoresis and immunofixation for Multiple Myeloma trials, leading to the implementation of several IF reflex assays for teasing out monoclonal antibody interferences. As from May 2017, she joined Barc Lab as Principal Scientist.


Immuno-Oncology Brochure Case Study - Multiple Myeloma